| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201,1 Israel Institute for Biological Research, Ness Ziona, Israel,2 Centre pour le Développement des Vaccins, Bamako, Mali,3 National Salmonella Reference Laboratory, Centers for Disease Control and Prevention, Atlanta, Georgia 30333,4 Centro para Vacunas en Desarrollo, Hospital de Niños Roberto del Rio, Servicio de Salud Metropolitano Norte, Santiago, Chile5
Received 18 January 2008/ Returned for modification 3 March 2008/ Accepted 11 March 2008
PCR methodology was developed to identify Salmonella enterica serovars Typhi, Paratyphi A, and Paratyphi B. One multiplex PCR identifies serogroup D, A, and B and Vi-positive strains; another confirms flagellar antigen "d," "a," or "b." Blinded testing of 664 Malian and Chilean Salmonella blood isolates demonstrated 100% sensitivity and specificity.
Published ahead of print on 26 March 2008.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|